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PIAS1The transcription factor estrogen receptor b (ERb) plays roles in the central nervous, endocrine, car-
diovascular, and immune systems. ERb can be SUMOylated. However, the underlying mechanism
remains unclear. Here, we show that RSRC1/SRrp53 interacts with ERb and SUMOylation of RSRC1
is required for regulation of PIAS1-mediated ERb SUMOylation. RSRC1 promotes ERb SUMOylation
through enhanced interaction between ERb and PIAS1. RSRC1 represses ERb transcriptional activity
through regulation of ERb SUMOylation. By establishing RSRC1 as a novel cofactor for SUMOylation,
our data provide insight into regulation of ERb SUMOylation and indicate that SUMOylation of one
protein can regulate another protein SUMOylation.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Protein SUMOylation is recognized as an important regulatory
mechanism for protein function. The SUMO pathway is achieved
through three enzymes: the E1 activating enzyme SAE1/2, the
E2-conjugating enzyme Ubc9 and one of a growing number of dis-
tinct E3 ligases. There are three classes of E3 ligases: the nucleo-
porin RanBP2 [1], the polycomb repressor Pc2 [2], and the PIAS
ligase family members. Most reported SUMO substrates are
nuclear proteins. SUMOylation is involved in nuclear activities,
such as DNA replication, genome stability [3], and gene transcrip-
tion [4]. SUMOylation also has effects on subcellular localization
and protein–protein interactions [5]. A number of SUMO target
proteins, including RanGAP1, MEK [6] and HIF-1a [7–8], have been
identiﬁed.Estrogen receptors (ERa and ERb) are indispensable for devel-
opment and play critical roles in female and male reproductive
physiology [9]. ERs also play important roles in maintenance of
bone mass as well as in the cardiovascular, central nervous and
immune systems [10–11]. Both ERa and ERb have been shown to
be involved in the development and progression of many types
of cancer [12–15]. ERb belongs to a superfamily of nuclear
receptors that act as ligand-activated transcription factors. ERb
contains N-terminal estrogen-independent and C-terminal
estrogen-dependent activation function domains (AF1 and AF2,
respectively). The DNA-binding domain of ERb is centrally located
[16]. It has been reported that ERb is modiﬁed at lysine 4 (K4) by
SUMO1 [17]. SUMO1 attachment inhibits ERb degradation by com-
peting with ubiquitin at the same acceptor site and dictates ERb
transcriptional inhibition in breast cancer cells. However, the
mechanism of ERb SUMOylation remains unclear. Especially, the
E3 ligase in this process has not been identiﬁed.
Arginine (R)/serine (S)-rich coiled-coil 1 (RSRC1) belongs to the
RS-domain-containing protein family [18]. The protein consists of
334 amino acids, with a molecular mass of 53kDa, so it is also ter-
med SRrp53 (serine/arginine-rich protein of 53kDa). The disparity
between predicted molecular weight of RSRC1 (38.7kDa) and
observed migration on SDS–PAGE (53kDa) is due to phosphoryla-
tion of RSRC1 [18]. RSRC1 contains an RS domain rich in serines
and arginines, followed by a helical region named coiled-coil
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been reported that RSRC1 is involved in the regulation of
pre-mRNA splicing. However, other functions of RSRC1 are almost
unknown. In this study, we demonstrate that RSRC1 can be
SUMOylated by the SUMO E3 ligases PIAS1/3. RSRC1 interacts with
ERb and SUMOylation of RSRC1 is required for the regulation of
PIAS1-mediated ERb SUMOylation. RSRC1 represses ERb transcrip-
tional activity through regulation of ERb SUMOylation.
2. Materials and methods
2.1. Plasmids
Expression plasmids for Flag-tagged, Myc-tagged, HA-tagged
proteins and their derivative mutants were constructed by insert-
ing PCR-generated fragments into pcDNA3 tagged with Flag, Myc
or HA (Invitrogen). Expression vectors for GST-tagged proteins
and protein fragments were generated by cloning PCR-generated
fragments into pGEX-KG (Invitrogen). The mutants for RSRC1 and
ERb were generated using PCR-directed mutagenesis.
2.2. Yeast two-hybrid assay
The bait plasmid pGBKT7-ERb-DBD (131–324) was used to
screen a human mammary gland cDNA library fused to the GAL4
activation domain in pACT2 (Clontech) per the manufacturer’s
instructions. Transformants were plated on synthetic medium
lacking tryptophan, leucine, adenine and histidine but containing
1 mM 3-aminotriazole. Approximately one million colonies were
screened. The candidate clones were rescued from the yeast cells
and reintroduced back to the same yeast strain to conﬁrm the
interaction between the candidates and the ERb DBD bait. The
speciﬁcity of the interaction was examined by comparing the inter-
actions between the candidates and various bait constructs. The
unrelated prey plasmid pACT2-lamin and the empty vector
pACT2 were used as negative controls.
2.3. Cell culture and transfections
HEK293T embryonic kidney cells and MDA-MB-231,
MDA-MB-435, and MDA-MB-468 human breast cancer cells were
routinely cultured at 37 C and 5% CO2 in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% fetal bovine serum
(FBS). For hormone treatment experiments, cells were cultured in
medium containing phenol red-free DMEM supplemented with
10% charcoal/dextran treated FBS. For transient transfection,
VigoFect reagent was used for transfections following the manu-
facture’s protocol (Vigorous Biotechnology). RSRC1 short hairpin
RNA1 (shRNA1) was purchased from Santa Cruz Biotechnology.
The target sequence for RSRC1 shRNA2 sequence was 50-GTACTT
CATCATCCAGTAC-30. The target sequences for PIAS1 shRNA1 and
PIAS1 shRNA2 were 50-GGAATAAGGAATCCG GATC-30 and 50-CTTC
AGAGGTTACGAGCAA-30, respectively.
2.4. Coimmunoprecipitation (Co-IP)
Cells were plated in 6-well plates at a density of 2  106 cells per
plate. Thirty hours after transfection, cellswere collected in PBS, and
cell extracts were prepared in IP buffer (20 mMTris, pH8.0, contain-
ing 125 mM NaCl, 0.125% NP-40, 5 mM EDTA, and protease inhibi-
tors). Coimmunoprecipitation was performed as previously
described [19]. For endogenous protein–protein interaction,
MDA-MB-231 cells were lysedwith IP Buffer. Precleared cell lysates
were incubated with anti-ERb (Millipore) or control IgG (Santa Cruz
Biotechnology), followed by incubation with protein G Sepharose.
The immunoprecipitates were washed three times with IP buffer,and the bound proteins were resolved by SDS–PAGE, followed by
standard Western blot analysis with anti-RSRC1 (Santa Cruz
Biotechnology) or anti-ERb (Novus Biologicals).
2.5. Luciferase reporter assay
MDA-MB-435, MDA-MB-468 and HEK 293T cells were plated in
a 24-well plate at a density of 1  105 cells/well. Twenty-four
hours later, cells were transfected with indicated plasmids, and
the respective empty vector was used to adjust the total
amount of DNA. Transfected cells were cultured in medium
containing phenol red-free DMEM supplemented with 10%
charcoal/dextran-treated FBS and were treated with 10 nM
17b-estradiol (E2) for 24 h. Cell extracts were assessed for lucifer-
ase activity as described previously [20].
2.6. Cellular SUMOylation assay
Cells were transfected with indicated plasmids. Twenty-four
hours after transfection, cells were treated with vehicle or 10 nM
E2 for 24 h and then harvested in IP buffer containing 20 mM
N-ethylmaleimide (Sigma–Aldrich). Co-IP was performed as men-
tioned above.
2.7. Quantitative reverse-transcription (RT)-PCR (RT-qPCR)
Total RNA was puriﬁed using TRIzol Reagent (Invitrogen) and
reverse transcribed with SuperScript II Reverse Transcriptase
(Invitrogen). RT-qPCR was performed as described previously [16].
The primers were listed as follows: PR-B sense, 5-CGCGCTCTACC-
CTGCACTC-3; PR-B antisense, 5-TGAATCCGGCCTCAGGTAGTT-3;
b-actin sense, 5-ATCACCATTGGCAATGAGCG-3; b-actin antisense,
5-TTGAAGGTAGTTTCGTGGAT-3.
2.8. Statistical analysis
Statistical signiﬁcance was determined by Student’s t-test. A P
value < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Interaction of ERb with RSRC1 protein
To identify ERb-interacting proteins, we screened a human
mammary cDNA library using amino acids 131–324 of ERb con-
taining part of hinge region and entire DBD domain as bait in the
yeast two-hybrid system. RSRC1 was identiﬁed as an
ERb-interacting protein (Fig. 1A). The speciﬁcity of this interaction
was veriﬁed in a direct two-hybrid binding assay with several con-
trols (Fig. 1A).
To address whether RSRC1 interacts with ERb in mammalian
cells, co-IP assays were performed in HEK293T cells. Consistent
with the results of the yeast two-hybrid system, Flag-tagged ERb
(Flag-ERb) coimmunoprecipitated Myc-tagged RSRC1
(Myc-RSRC1) in HEK293T cells in the presence or absence of E2
(Fig. 1B). RSRC1 also interacted with ERa (Supplemental Fig. 1).
This may be due to the homology between ERa and ERb.
Importantly, endogenous RSRC1 associated with endogenous ERb
in MDA-MB-231 breast cancer cells, indicating physiological inter-
action between RSRC1 and ERb (Fig. 1C).
3.2. Mapping of the ERb and RSRC1 interaction domains
Since the region of ERb containing the DBD domain interacts
with RSRC1 in yeast two-hybrid system, we tested whether the
Fig. 1. Interaction of ERb with RSRC1 protein. (A) Identiﬁcation of RSRC1 as an ERb-interacting protein by the yeast two-hybrid assay. Yeast AH109 cells were transformed
with the indicated plasmids (bait plus prey). +, grown within 96 h; , no growth within 96 h. Positive colonies were tested for b-galactosidase (b-gal) activity. +, turned blue
within 2 h; , did not turn blue within 2 h. (B) HEK293T cells were transfected with Myc-tagged RSRC1 (Myc-RSRC1) and Flag-tagged ERb (Flag-ERb) or empty vector, and
were treated with 10 nM 17b-estradiol (E2). Co-IP assay was carried out with an anti-Flag antibody, followed by immunoblotting (IB) with the indicated antibodies. MW,
molecular weight. (C) Cell lysates fromMDA-MB-231 cells were immunoprecipitated with normal serum (IgG) or an anti-ERb antibody, followed by immunoblotting with the
indicated antibodies.
Fig. 2. Mapping of the ERb and RSRC1 interaction domains. (A) HEK293T cells were transfected with Flag-tagged RSRC1 and Myc-tagged AF1, DBD, and AF2 domains of ERb, as
indicated. (B) HEK293T cells were transfected with Flag-tagged ERb and Myc-tagged RSRC1 or RSRC1 deletion mutants. Co-IP assay was performed with an anti-Myc antibody,
followed by immunoblotting with the indicated antibodies (A and B). Also shown at top of the graph is a schematic diagram of the ERb (A) or RSRC1 (B) protein, illustrating
the locations of various domains and SUMOylation sites (K4 in ERb, and K196 and K230 in RSRC1).
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co-IP experiments showed that the DBD domain, but not the AF1
and AF2 domains, associated with RSRC1 in HEK293T cells
(Fig. 2A).
To deﬁne the region of RSRC1 required for its interaction with
ERb, RSRC1 was divided into four fragments according to the
RSRC1 structure (Fig. 2B). The binding abilities of distinct RSRC1
fragments with ERb were determined by co-IP experiments.
RSRC1(1–224), but not RSRC1(1–140) and RSRC1(1–180), inter-
acted with ERb, suggesting that the region 180–224 containing
the coiled-coil domain is required for the ERb/RSRC1 interaction
(Fig. 2B).3.3. RSRC1 is SUMOylated at K196 and K230 by SUMO1 and the E3
ligases PIAS1 and PIAS3
Since the function of RSRC1 is almost unknown, we used yeast
two-hybrid screen again to screen RSRC1-interacting proteins,
with the full-length coding sequence of RSRC1 as bait. We identi-
ﬁed SUMO1 and the SUMO E3 ligases PIAS1 and PIAS3 as
RSRC1-interacting proteins (Fig. 3A). Co-IP experiments showed
that PIAS1 and PIAS3 bound to RSRC1 with similar afﬁnity in
HEK293T cells (Fig. 3B). PIAS1 interacted with RSRC1(1–140) con-
taining the RS domain, but not RSRC1(140–334) containing the
coiled-coil domain (Fig. 3C).
Fig. 3. RSRC1 interacts with PIAS1/3 and is SUMOylated at K196 and K230. (A) Identiﬁcation of SUMO1, PIAS1 and PIAS3 as RSRC1-interacting proteins by the yeast two-
hybrid assay. Yeast AH109 cells were transformed with the indicated plasmids (bait plus prey) and analyzed as described in the legend to Fig. 1A. (B) HEK293T cells were
transfected with Flag-RSRC1 and Myc-tagged PIAS1 or PIAS3. Co-IP assay was performed with an anti-Myc antibody, followed by immunoblotting with the indicated
antibodies. (C) HEK293T cells were transfected with Flag-PIAS1 and Myc-tagged RSRC1 or RSRC1 deletion mutants. Co-IP assay was performed as in (B). (D) MDA-MB-468
whole cell lysate was immunoprecipitated with anti-SUMO1 agarose or anti-FLAG agarose (negative control), followed by immunoblotting with the indicated antibodies. The
molecular weight of the RSRC1 SUMOylation band is approximately 70kDa. (E) HEK293T cells were transfected with the indicated plasmids. Co-IP assay was performed with
an anti-Flag antibody, followed by immunoblotting with the indicated antibodies. (F) HEK293T cells were transfected with HA-SUMO1 and Flag-tagged RSRC1 or indicated
RSRC1 point mutation constructs. Co-IP assay was performed as in (E). (G) HEK293T cells were transfected with HA-SUMO1 and Flag-tagged RSRC1 or its double point mutant
Flag-RSRC1(K196/230R). Co-IP assay was performed as in (D). The densitometric quantitation of relative RSRC1 SUMOylation from 3 independent experiments is shown
(mean ± S.D.) (E–G). *P < 0.05 versus corresponding control.
L. Chen et al. / FEBS Letters 589 (2015) 1476–1484 1479
1480 L. Chen et al. / FEBS Letters 589 (2015) 1476–1484Because RSRC1 interacts with PIAS1/PIAS3 and SUMO1,we spec-
ulated that RSRC1might be SUMOylated, andPIAS1 andPIAS3might
be E3 ligases for RSRC1. Indeed, RSRC1 could be SUMOylated by
SUMO1, and PIAS1 and PIAS3 strongly enhanced the SUMOylation
of RSRC1 similarly (Fig. 3D and E). Most SUMO-modiﬁed proteins
contain the tetrapeptide consensusmotifW-K-x-D/E (whereW rep-
resents a hydrophobic amino acid and x represents any amino acid).
According to SUMOplot™ Analysis Program that predicts the prob-
ability for the SUMO consensus sequence to be engaged in SUMO
attachment (www.abgent.com/sumoplot), K146, K163, K196, and
K215 of RSRC1were predicted to be the potential SUMOylated sites.
In addition,wemanually selected K230 andK261,whichmost prob-
ably match the consensus motif, as potential SUMOylated sites of
RSRC1. Compared to wide type RSRC1, mutation at K196 or K230,
but not at the other sites, decreased RSRC1 SUMOylation levels
(Fig. 3F). When both K196 and K230 were mutated to arginine (R),
little SUMO1 was attached to the double mutant (Fig. 3G). These
data indicate that RSRC1 is SUMOylated at K196 and K230 by
SUMO1 and the E3 ligases PIAS1 and PIAS3. K196 (AKAD) matches
the SUMO consensus sequence, whereas K230 (VKEI) does not.
3.4. RSRC1 SUMOylation promotes ERb SUMOylation
ERb has been shown to be SUMOylated by SUMO1 [17]. We also
demonstrated endogenous SUMOylation of ERb (Fig. 4A). The
observation that RSRC1 interacts with ERb, PIAS1/3 and SUMO1
raises the possibility that RSRC1 SUMOylation may regulate ERb
SUMOylation. Indeed, RSRC1 overexpression enhanced ERb
SUMOylation in HEK293T cells (Fig. 4B). However, RSRC1 overex-
pression did not increase the SUMOylation of ERa and proges-
terone receptor-B (PR-B) (Fig. 4B), suggesting that RSRC1
speciﬁcally promotes ERb SUMOylation and the interaction
between RSRC1 and ERa is not sufﬁcient for regulation of ERa
SUMOylation. In contrast, knockdown of RSRC1 decreased ERb
SUMOylation in MDA-MB-231 cells (Fig. 4C). RSRC1 promoted
ERb SUMOylation in the presence and absence of E2 (Fig. 4D).
ERb has been reported to be SUMOylated at K4 [17]. We then
tested the effects of RSRC1 on ERb(K4R) SUMOylation. As expected,
the mutant ERb(K4R) could not be SUMOylated (Fig. 4E).
Importantly, RSRC1 failed to regulate ERb(K4R) SUMOylation, sug-
gesting that RSRC1 regulate ERb SUMOylation at K4 (Fig. 4E).
Next, we investigated whether ERb SUMOylation regulated by
RSRC1 depends on the RSRC1/ERb interaction. Since the
coiled-coil domain of RSRC1 is required for the ERb/RSRC1 interac-
tion, we constructed RSRC1(D180–224) in which the coiled-coil
domain was deleted. RSRC1(D180–224) failed to enhance ERb
SUMOylation (Fig. 4F), suggesting that the coiled-coil domain of
RSRC1 is necessary for enhancement of ERb SUMOylation.
To test whether RSRC1 SUMOylation is critical for enhancement
of ERb SUMOylation, the effects of RSRC1 and the mutant
RSRC1(K196/K230R) that loses the SUMOylation of RSRC1 on ERb
SUMOylation were compared. In contrast to wide-type RSRC1,
RSRC1(K196/230R) failed to enhance ERb SUMOylation (Fig. 4G).
These data suggest that RSRC1 enhancement of ERb SUMOylation
depends on RSRC1 SUMOylation.
3.5. PIAS1 is a SUMO E3 ligase for ERb
Although ERb has been reported to be SUMOylated, whether
SUMO E3 ligase is involved in this process is unknown. Since
RSRC1 interacts with the E3 ligases PIAS1 and PIAS3, and RSRC1
can regulate ERb SUMOylation, we tested the effects of PIAS1/3
on ERb SUMOylation. Overexpression of PIAS1, but not PIAS3,
potently enhanced ERb SUMOylation (Fig. 5A). In contrast, PIAS1
knockdown decreased ERb SUMOylation (Fig. 5B). Moreover,
co-IP experiments showed that PIAS1 interacted with ERb(Fig. 5B). The AF2 domain of ERb bound to PIAS1 (Fig. 5C). Taken
together, these results established PIAS1 as an E3 ligase for ERb.
3.6. RSRC1 promotes ERb SUMOylation through enhanced interaction
between PIAS1 and ERb
To investigate the mechanism by which RSRC1 promotes ERb
SUMOylation, we investigated whether RSRC1 alters the interac-
tion between PIAS1 and ERb. Indeed, RSRC1 overexpression
enhanced the PIAS1/ERb interaction in HEK293T cells, whereas
the RSRC1(K196, 230R) and RSRC1(D180–224) mutants, both of
which fail to promote ERb SUMOylation, did not (Fig. 5D). In con-
trast to RSRC1 overexpression, RSRC1 knockdown reduced the
interaction between PIAS1 and ERb (Fig. 5E). Moreover, PIAS1
knockdown completely abolished the ability of RSRC1 to enhance
ERb SUMOylation (Fig. 5F). These results suggest that RSRC1 regu-
lates ERb SUMOylation through enhanced PIAS1/ERb interaction.
3.7. RSRC1 represses ERb transcriptional activity through regulation of
ERb SUMOylation
Many overexpression studies have shown that SUMOylation
represses the transcriptional activity of transcription factors [4].
SUMOylation of some transcription factors ﬁne-tunes their actions
[21–27]. As previously reported [17], ERb SUMOylation inhibited
its transcriptional activity because the ERb(K4R) mutant in
which the ERb SUMOylation site was mutated increased
estrogen-responsive element-containing luciferase (ERE-Luc)
reporter activity compared to wild-type ERb in ERb-negative
HEK293T cells (Fig. 6A). Importantly, RSRC1 overexpression
decreased ERb transcriptional activity, whereas overexpression of
the RSRC1(K196, 230R) mutant that fails to regulate ERb
SUMOylation did not. Mutation of ERb K4 to R totally abolished
the ability of RSRC1 to regulate ERb transcriptional activity
(Fig. 6A). Similar results were observed in ERb-negative
MDA-MB-435 and MDA-MB-468 breast cancer cells
(Supplemental Fig. 2). In contrast to RSRC1 overexpression,
RSRC1 knockdown increased ERb transcriptional activity (Fig. 6B).
Like RSRC1, PIAS1 also inhibited ERb transcriptional activity. The
maximal inhibition was observed when RSRC1 and PIAS1 were
coexpressed (Fig. 6C). In contrast, PIAS1 knockdown abolished
the ability of RSRC1 to inhibit ERb transcriptional activity
(Fig. 6D). Consistent with the results of the transcriptional activity
assays, RSRC1 overexpression decreased the transcription of the
ERb target gene PR (Fig. 6E). Taken together, these data indicate
that RSRC1 represses ERb transcriptional activity through modula-
tion of ERb SUMOylation.4. Discussion
ERb protein undergoes several posttranslational modiﬁcations,
including phosphorylation, ubiquitilation and SUMOylation, which
may affect ERb transcriptional activation, protein stability, subcel-
lular localization, and altered protein–protein interactions [28].
Protein SUMOylation consists of three discrete enzymatic steps:
activation, involving the E1 enzyme (SAE1/SAE2); conjugation,
involving the E2 enzyme (Ubc9); substrate modiﬁcation, through
the cooperation of the E2 and E3 protein ligases. It has been
reported that Ubc9-mediaed SUMOylation of ERb at K4 resulted
in inhibition of transcription activity [17]. In this study, we have
identiﬁed PIAS1 as a SUMO E3 ligase for ERb. First, PIAS1 physically
interacts with ERb. Second, ectopic PIAS1 expression promotes ERb
SUMOylation. Finally, knockdown of PIAS1 greatly represses ERb
SUMOylation. These data indicate that ERb is a new substrate of
PIAS1 and PIAS1 is essential for ERb SUMOylation.
Fig. 4. RSRC1 SUMOylation enhances ERb SUMOylation. (A) MDA-MB-468 whole cell lysate was immunoprecipitated with anti-SUMO1 agarose or anti-FLAG agarose
(negative control), followed by immunoblot with the indicated antibodies. The molecular weight of the ERb SUMOylation band is approximately 70kDa. (B) HEK293T cells
were transfected with HA-SUMO1, Myc-RSRC1 and Flag-tagged ERa, ERb, or PR-B, as indicated. Co-IP assay was performed with an anti-Flag antibody, followed by
immunoblotting with the indicated antibodies. The arrows indicate corresponding SUMOylated proteins. (C) MDA-MB-231 cells stably transfected with RSRC1 shRNA or
control shRNA were transiently transfected with Flag-ERb and HA-SUMO1. Co-IP assay was performed as in (B). GAPDH was used as a loading control. (D) HEK293T cells were
transfected with Flag-ERb, HA-SUMO1, and Myc-RSRC1, as indicated. Transfected cells were treated with 10 nm E2 and analyzed as in (B). (E) HEK293T cells were transfected
with HA-SUMO1, Myc-RSRC1, and Flag-tagged ERb or its mutant Flag-ERb(K4R), as indicated. Co-IP assay was performed as in (B). (F) HEK293T cells were transfected with
Flag-ERb, HA-SUMO1, and Myc-tagged RSRC1 or RSRC1(D180–224), as indicated. Co-IP assay was performed as in (B). (G) HEK293T cells were transfected with Flag-ERb, HA-
SUMO1, and Myc-tagged RSRC1 or RSRC1(K196/230R), as indicated. Co-IP assay was performed as in (B). The densitometric quantitation of relative ERb SUMOylation from 3
independent experiments is shown (mean ± S.D.) (C–G). *P < 0.05 versus corresponding control.
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Fig. 5. RSRC1 promotes ERb SUMOylation through increased interaction between PIAS1 and ERb. (A) HEK293T cells were transfected with Myc-PIAS1 or Myc-PIAS3, Flag-ERb,
and HA-SUMO1, as indicated. Co-IP assay was performed with an anti-Flag antibody, followed by immunoblotting with the indicated antibodies. (B) MDA-MB-468 cells were
transfected with PIAS1 shRNA1 or control shRNA. Co-IP assay was performed as described in the legend to Fig. 4A. (C) HEK293T cells were transfected with Flag-tagged PIAS1
and Myc-tagged AF1, DBD, and AF2 domains of ERb, as indicated. Co-IP assay was performed with an anti-Myc antibody, followed by immunoblotting with the indicated
antibodies. (D) HEK293T cells were transfected with Flag-ERb, Myc-PIAS1, and HA-tagged RSRC1, RSRC1(K196, 230R) or RSRC1(D180–224), as indicated. Co-IP assay was
performed with an anti-Myc antibody, followed by immunoblotting with the indicated antibodies. (E) HEK293T cells were transfected with Flag-ERb, Myc-PIAS1, and RSRC1
shRNA or control shRNA, as indicated. Co-IP assaywas performed as in (D). The RSRC1 knockdown effect were shown (right panel). (F) HEK293T cells were transfectedwith HA-
SUMO1, Flag-ERb, Myc-RSRC1, and control shRNA, PIAS1 shRNA1 or PIAS1 shRNA2, as indicated. Co-IP assay was performed as in (A). The PIAS1 knockdown effect were shown
(right panel). The densitometric quantitation of relative ERb SUMOylation from 3 independent experiments is shown (mean ± S.D.). *P < 0.05 versus corresponding control.
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Fig. 6. RSRC1 inhibits ERb transcriptional activity through regulation of ERb SUMOylation. (A) HEK293T cells were transfected with ERE-luc, ERb or ERb(K4R), and RSRC1 or
RSRC1(K196/230R), as indicated. Cells were then treated with 10 nM E2 for 24 h and harvested for luciferase activity measurement. (B) HEK293T cells were transfected with
RSRC1 shRNA1/2 or control shRNA. Cells were treated and analyzed as in (A). The RSRC1 knockdown effect were shown (lower panel). (C) HEK293T cells were transfected
with ERE-luc, ERb, and PIAS1 or PIAS1 plus RSRC1. Cells were treated and analyzed as in (A). (D) HEK293T cells were transfected with ERE-luc, ERb, RSRC1, and PIAS1 shRNA1
or control shRNA. Cells were treated and analyzed as in (A). (E) MDA-MB-468 cells stably expressing ERb were transfected with empty vector or Flag-RSRC1. Cells were then
treated with 10 nM E2 for 24 h and harvested for RT-qPCR assays. Data shown are mean ± S.D. of triplicate measurements and have been repeated 3 times with similar results
(*P < 0.05).
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receptor (AR), progesterone receptor (PR), glucocorticoid receptor
(GR), and mineralocorticoid receptor (MR), have been reported to
be modiﬁed by SUMOylation (17, 21–27). AR, PR, GR, and MR are
SUMOylated at a lysine residue embedded in the SUMOylation
consensus sequence, whereas ERa and ERb are SUMOylated at a
non-consensus lysine residue. The SUMO E2 conjugating enzyme
Ubc9 can catalyze SUMOylation of AR, GR and MR in vitro.
However, in vitro translated ERa and ERb are not SUMOylated in
the presence of Ubc9. Both PIAS1 and PIAS3 act as SUMO E3Ligases for ERa Sumoylation. PIAS1, but not PIAS3, is a SUMO E3
ligase for ERb. SUMOylation of ERb, AR, PR, and MR seem to
represse their transcriptional activity because SUMOylation site
mutation increases their transcriptional activity. In contrast,
SUMOylation of ERa and GR potentiate their transcriptional
activity.
SUMO E3 ligases contribute to SUMOylation substrate speci-
ﬁcity and efﬁciency. PIAS proteins act as adaptor proteins that
bridge the SUMO-conjugated E2 enzyme and the substrate in the
SUMOylation reaction. Five major PIAS isoforms, PIAS1,
1484 L. Chen et al. / FEBS Letters 589 (2015) 1476–1484PIAS2a/Xa and 2b/Xb, PIAS3 and PIAS4/y have been identiﬁed.
Many proteins have been reported to be targets of PIAS ligeses.
For example, PIAS1 and PIASxb, act as speciﬁc E3 ligases that
promote SUMOylation of the tumor suppressor p53 and repress
transcriptional activity of p53 [29–30]. In this study, like ERb,
RSRC1 is also identiﬁed as a new substrate of PIAS proteins.
However, both PIAS1 and PIAS3 regulate RSRC1 SUMOylation,
whereas PIAS1, but not PIAS3, modulate ERb SUMOylation, indicat-
ing that SUMO E3 ligases have substrate speciﬁcity.
Different domains of ERb interact with RSRC1 and PIAS1. The
DBD (aa 146–250) and AF2 (aa 251–530) domains of ERb associate
with RSRC1 and PIAS1, respectively (Figs. 2A and 5C). Since RSRC1
increases the interaction between PIAS1 and ERb (Fig. 5D and E),
these data suggest that RSRC1, PIAS1 and ERb form a complex.
However, PIAS1 does not interact with the region of ERb containing
the K4 SUMOylation site. Such situation also exists in a previous
study showing that the region 1–126 of NEMO is sufﬁcient to inter-
act with the SUMO E3 ligase PIASy, but the SUMOylation sites of
NEMO are K277 and K309 [31]. Like E3 ubiquitin ligases, the
RSRC1-PIAS1 complex might promote SUMO1 transfer from E2
enzyme to K4 of ERb, although the underlying mechanism remains
to be investigated.
RSRC1 has been reported to regulate pre-mRNA splicing via a
serine- and arginine-rich domain termed the RS domain [18].
Many proteins have RS domains. RS domains have been demon-
strated to directly contact the pre-mRNA branch point and pro-
mote protein–protein interactions that are essential for the
recruitment of the splicing apparatus and for splice site pairing.
The fact that RSRC1 binds to PIAS1 via the RS domain and is
SUMOylated by PIAS1 suggests that RS domains mediate protein–
protein interactions that are critical for the recruitment of SUMO
E3 ligases. RSRC1 promotes PIAS1-mediated ERb SUMOylation
through enhanced interaction of ERb with the SUMO E3 ligase
PIAS1, suggesting that RSRC1 is a novel coactivator for protein
SUMOylation. Interestingly, RSRC1 itself can be SUMOylated by
PIAS proteins. Whether RSRC1 SUMOylation affects pre-mRNA
splicing remains to be investigated. Our observation that the
RSRC1(K196, K230R) mutant in which the SUMOylation sites of
RSRC1 are mutated fails to enhance ERb SUMOylation and tran-
scriptional activity indicates that SUMOylation of RSRC1 itself is
essential for enhancement of ERb SUMOylation transcriptional
activity. Our data further suggest that, in a similar way to protein
phosphorylation cascades [32], SUMOylation of one protein can
regulate another protein SUMOylation.
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